BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$27.05 USD
+0.35 (1.31%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $27.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BBIO 27.05 +0.35(1.31%)
Will BBIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BBIO
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
BBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Other News for BBIO
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
BridgeBio Pharma appoints Thomas Trimarchi COO
BridgeBio appoints Trimarchi as President, COO
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biotech Alert: Searches spiking for these stocks today